PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 12 | 2 | 125-139
Article title

Leczenie chirurgiczne zaawansowanego raka szyjki macicy a wytrzewienie – przeglad literatury

Content
Title variants
EN
Surgical therapy and exenteration for advanced cervical cancer – literature review
Languages of publication
EN PL
Abstracts
EN
While the surgical technique of exenteration has been around for 60 years now, recent progress in the development of reconstructive surgery has created new opportunities for gastrointestinal and urinary tract anastomosis. As pre- and postoperative care has improved and indications for the exenteration procedure have became more precise, the outcomes of the treatment for advanced malignant pelvic tumors have also improved. Consequently, the perioperative mortality rate has decreased from the 28% specified by Brunschwig to the present rate of 3%. Moreover, the number of complications resulting from such complex procedures has decreased. Today, postoperative complications are no longer a factor that impacts how eligibility for exenteration is decided. It has been demonstrated that the quality of life of patients subject to exenteration procedure compared to those having palliative chemotherapy is lower in the first months following surgery, but is higher in the long-term follow-up beginning 9 months after the procedure. At the same time, multiple studies have unambiguously demonstrated that the overall five-year survival rate in patients with cervical cancer recurrence after radiation therapy is the longest upon exenteration and, subject to strict following of the indications for the procedure, allows a survival rate of 50% to be exceeded in this group of patients. Since the exenteration procedure is the culmination of a combined treatment, eligibility for such a procedure should entail multiple factors related to the course of treatment and the biology of a given neoplasm and should be decided only by an interdisciplinary team composed of at least a radiation therapist, a gynecologist-oncologist, and a clinical oncologist. Also, surgery of this kind is of a disciplinary nature therefore the procedure should be performed only in a reference site employing gynecologists, oncologists, urologists, and oncological surgeons who have comprehensive surgical experience. Only sites that employ such health care professionals allow for the safe performance of the exenteration procedure.
PL
Technika zabiegu wytrzewienia znana jest od 60 lat. Jednak postęp, jaki dokonał się w rozwoju chirurgii rekonstrukcyjnej, stworzył nowe możliwości odtworzenia ciągłości przewodu pokarmowego i dróg moczowych. W efekcie ulepszania opieki przed- i pooperacyjnej oraz uściślenia wskazań do tego zabiegu poprawiły się wyniki leczenia zaawansowanych nowotworów złośliwych rozwijających się w miednicy. Śmiertelność okołooperacyjna zmniejszyła się obecnie z 28% opisywanych przez Brunschwiga do 3%. Liczba powikłań po tak rozległej operacji także znacznie się zmniejszyła. Dzisiaj powikłania nie są już czynnikiem wpływającym na podjęcie decyzji o kwalifikacji do wykonania tego zabiegu. Wykazano, że jakość życia chorych po wytrzewieniu w porównaniu z paliatywną chemioterapią jest gorsza tylko w pierwszych miesiącach po zabiegu, a z wieloletniej obserwacji wynika również, że od 9. miesiąca po operacji jakość życia jest nawet lepsza. Z wielu badań jednoznacznie wynika też, że całkowite przeżycie 5-letnie u pacjentek ze wznową raka szyjki macicy po radioterapii jest najdłuższe po leczeniu polegającym na wytrzewieniu, przy ściśle przestrzeganych wskazaniach do zabiegu, i pozwala w tej grupie chorych przekroczyć 50%. Ponieważ jest to operacja, która wieńczy niejako leczenie skojarzone, kwalifikacja do niego powinna uwzględniać wiele czynników związanych z dotychczasowym przebiegiem terapii oraz z biologią danego nowotworu i być podejmowana wyłącznie przez interdyscyplinarne zespoły, składające się co najmniej z radioterapeuty, ginekologa onkologa i onkologa klinicznego. Chirurgia w takim przypadku również ma charakter interdyscyplinarny, dlatego zabieg ten należy wykonywać jedynie w ośrodkach referencyjnych, w których doświadczenie chirurgiczne przenika pomiędzy ginekologami onkologami, urologami i chirurgami onkologami. Tylko ośrodki zatrudniające lekarzy o dużym doświadczeniu chirurgicznym mogą zapewnić bezpieczny przebieg zabiegu wytrzewienia.
Discipline
Year
Volume
12
Issue
2
Pages
125-139
Physical description
References
  • 1. Iavazzo C., Gkegkes I.D.: Robotic technology for pelvic exenteration in cases of cervical cancer. Int. J. Gynaecol. Obstet. 2014; 125: 15–17.
  • 2. Kimmig R., Wimberger P., Buderath P. i wsp.: Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as “total mesometrial resection (TMMR)” by M Höckel translated to robotic surgery (rTMMR). World J. Surg. Oncol. 2013; 11: 211.
  • 3. Ungar L., Palfalvi L., Novak Z.: Primary pelvic exenteration in cervical cancer patients. Gynecol. Oncol. 2008; 111 (supl.): S9–S12.
  • 4. Brunschwig A., Daniel W.: Pelvic exenteration operations: with summary of sixty-six cases surviving more than five years. Ann. Surg. 1960; 151: 571–576.
  • 5. Brunschwig A.: Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1948; 1: 177–183.
  • 6. Magrina J.F., Stanhope C.R., Weaver A.L.: Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol. Oncol. 1997; 64: 130–135.
  • 7. Magrina J.F.: Types of pelvic exenterations: a reappraisal. Gynecol. Oncol. 1990; 37: 363–366.
  • 8. Chiva L.M., Lapuente F., González-Cortijo L. i wsp.: Surgical treatment of recurrent cervical cancer: state of the art and new achievements. Gynecol. Oncol. 2008; 110 (supl.): S60–S66.
  • 9. Meads C., Davenport C., Matysiak S. i wsp.: Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121: 398–407.
  • 10. Zanvettor P.H., Filho D.F., Neves A.R. i wsp.: Laparoscopic surgical staging of locally advanced cervix cancer (IB2 to IVA): initial experience. Gynecol. Oncol. 2011; 120: 358–361.
  • 11. Peiretti M., Zapardiel I., Zanagnolo V. i wsp.: Management of recurrent cervical cancer: a review of the literature. Surg. Oncol. 2012; 21: e59–e66.
  • 12. Höckel M., Dornhöfer N.: Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006; 7: 837–847.
  • 13. Huang M., Iglesias D.A., Westin S.N. i wsp.: Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecol. Oncol. 2014; 132: 114–118.
  • 14. Rezk Y.A., Hurley K.E., Carter J. i wsp.: A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. Gynecol. Oncol. 2013; 128: 191–197.
  • 15. Marnitz S., Dowdy S., Lanowska M. i wsp.: Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. Int. J. Gynecol. Cancer 2009; 19: 974–977.
  • 16. Young J.M., Badgery-Parker T., Masya L.M. i wsp.: Quality of life and other patient-reported outcomes following exenteration for pelvic malignancy. Br. J. Surg. 2014; 101: 277–287.
  • 17. Ferenschild F.T., Vermaas M., Verhoef C. i wsp.: Total pelvic exenteration for primary and recurrent malignancies. World J. Surg. 2009; 33: 1502–1508.
  • 18. De Wilt J.H., van Leeuwen D.H., Logmans A. i wsp.: Pelvic exenteration for primary and recurrent gynaecological malignancies. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 134: 243–248.
  • 19. Numa F., Ogata H., Suminami Y. i wsp.: Pelvic exenteration for the treatment of gynecological malignancies. Arch. Gynecol. Obstet. 1997; 259: 133–138.
  • 20. Schmidt A.M., Imesch P., Fink D., Egger H.: Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol. Oncol. 2012; 125: 604–609.
  • 21. Ungar L., Palfalvi L.: Pelvic exenteration without external urinary or fecal diversion in gynecological cancer patients. Int. J. Gynecol. Cancer 2006; 16: 364–368.
  • 22. Maggioni A., Roviglione G., Landoni F. i wsp.: Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol. Oncol. 2009; 114: 64–68.
  • 23. Yoo H.J., Lim M.C., Seo S.S. i wsp.: Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J. Gynecol. Oncol. 2012; 23: 242–250.
  • 24. Chiantera V., Rossi M., De Iaco P. i wsp.: Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients. Int. J. Gynecol. Cancer 2014; 24: 916–922.
  • 25. Höckel M.: Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol. Oncol. 2003; 91: 369–377.
  • 26. Höckel M., Horn L.C., Einenkel J.: (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. Gynecol. Oncol. 2012; 127: 297–302.
  • 27. Höckel M., Horn L.C., Tetsch E., Einenkel J.: Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy. Gynecol. Oncol. 2012; 125: 168–174.
  • 28. Höckel M.: Ultra-radical compartmentalized surgery in gynaecological oncology. Eur. J. Surg. Oncol. 2006; 32: 859–865.
  • 29. Ungár L., Pálfalvi L., Tarnai L. i wsp.: Surgical treatment of lymph node metastases in stage IB cervical cancer. The laterally extended parametrectomy (LEP) procedure: experience with a 5 year follow-up. Gynecol. Oncol. 2011; 123: 337–341.
  • 30. Höckel M., Horn L.C., Illig R. i wsp.: Ontogenetic anatomy of the distal vagina: relevance for local tumor spread and implications for cancer surgery. Gynecol. Oncol. 2011; 122: 313–318.
  • 31. Höckel M., Kahn T., Einenkel J. i wsp.: Local spread of cervical cancer revisited: a clinical and pathological pattern analysis. Gynecol. Oncol. 2010; 117: 401–408.
  • 32. Ungár L., Palfalvi L.: Surgical treatment of lymph node metastases in stage IB cervical cancer: the laterally extended parametrectomy (LEP) procedure. Int. J. Gynecol. Cancer 2003; 13: 647–651.
  • 33. Qiu S.S., Jurado M., Hontanilla B.: Comparison of TRAM versus DIEP flap in total vaginal reconstruction after pelvic exenteration. Plast. Reconstr. Surg. 2013; 132: 1020e–1027e.
  • 34. Pectasides D., Kamposioras K., Papaxoinis G., Pectasides E.: Chemotherapy for recurrent cervical cancer. Cancer Treat. Rev. 2008; 34: 603–613.
  • 35. Tao X., Hu W., Ramirez P.T., Kavanagh J.J.: Chemotherapy for recurrent and metastatic cervical cancer. Gynecol. Oncol. 2008; 110 (supl. 2): S67–S71.
  • 36. Tzioras S., Pavlidis N., Paraskevaidis E., Ioannidis J.P.: Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat. Rev. 2007; 33: 24–38.
  • 37. Kasamatsu T., Onda T., Yamada T., Tsunematsu R.: Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int. J. Gynecol. Obstet. 2005; 89: 39–44.
  • 38. Berek J.S., Howe C., Lagasse L.D., Hacker N.F.: Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol. Oncol. 2005; 99: 153–159.
  • 39. Iglesias D.A., Westin S.N., Rallapalli V. i wsp.: The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol. Oncol. 2012; 125: 336–342.
  • 40. Lin J.F., Berger J.L., Krivak T.C. i wsp.: Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol. Oncol. 2014; 132: 416–422.
  • 41. Benn T., Brooks R.A., Zhang Q. i wsp.: Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecol. Oncol. 2011; 122: 14–18.
  • 42. Husain A., Curtin J., Brown C. i wsp.: Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies. Gynecol. Oncol. 2000; 78: 208–211.
  • 43. Roos E.J., De Graeff A., van Eijkeren M.A. i wsp.: Quality of life after pelvic exenteration. Gynecol. Oncol. 2004; 93: 610–614.
  • 44. Chiantera V., Rossi M., De Iaco P. i wsp.: Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int. J. Gynecol. Cancer 2014; 24: 156–164.
  • 45. Khoury-Collado F., Einstein M.H., Bochner B.H. i wsp.: Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol. Oncol. 2012; 124: 42–47.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-f9b197ef-26c9-46ce-802d-8c40685cd136
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.